Arcadia Biosciences - RKDA Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings or view top-rated stocks.

1 brokerages have issued twelve-month target prices for Arcadia Biosciences' stock. Their RKDA share price forecasts range from $3.00 to $3.50. On average, they predict the company's stock price to reach $3.25 in the next year. This suggests a possible upside of 515.6% from the stock's current price.
View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts.

Arcadia Biosciences' stock was trading at $1.04 on January 1st, 2022. Since then, RKDA shares have decreased by 49.2% and is now trading at $0.5279.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our RKDA earnings forecast.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its earnings results on Thursday, August, 11th. The basic materials company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.14. The basic materials company had revenue of $3.86 million for the quarter, compared to analyst estimates of $2.28 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 80.56% and a negative net margin of 169.65%. During the same quarter in the prior year, the business posted ($0.26) earnings per share.

Arcadia Biosciences's stock reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

(RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RKDA stock can currently be purchased for approximately $0.53.

Arcadia Biosciences (NASDAQ:RKDA) has a market capitalization of $11.71 million and generates $6.78 million in revenue each year. The basic materials company earns $-14,660,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The official website for the company is www.arcadiabio.com. The basic materials company can be reached via phone at (530) 756-7077, via email at ir@arcadiabio.com, or via fax at 530-756-7027.